Skip to main content
. 2022 Mar 10;77(1):152–162. doi: 10.1016/j.jhep.2022.02.015

Fig. 4.

Fig. 4

Anti-SARS-CoV-2 s-RBD antibody titers in COVID-19-recovered and in COVID-19-naïve patients.

Anti-SARS-CoV-2 s-RBD antibody titers in COVID-19-recovered (light blue circles) and in COVID-19-naïve (white circles) patients evaluated before and after 3 weeks (19 days) of the first dose of Pfizer-BioNTech® BNT162b2 vaccine, as well as after 1 month (31±2 days), 4 months (125±5 days), and 6 months (165±4 days) following the second vaccine dose. Positive responders to vaccination were defined as those having reached an antibody titer ≥0.8 U/ml. Medians of antibody titers are reported for each time point.